Status:

COMPLETED

Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK

Lead Sponsor:

photonamic GmbH & Co. KG

Conditions:

Actinic Keratosis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The aim of this study is to investigate whether PD P 506 A-PDT is effective in treating mild to moderate AK lesions located on the head.

Detailed Description

Actinic keratosis (AK) is a pre-cancerous skin abnormality usually caused by sun exposure. Actinic keratoses occur most commonly in fair skin, especially in the elderly. They mainly occur in sun-expos...

Eligibility Criteria

Inclusion

  • Written informed consent
  • Caucasian patients
  • Diagnosis of actinic keratosis (AK) with at least three locally separated lesions located on head and/or face (hairless areas)
  • Selected AK study lesions have clearly defined margins and are mild to moderate
  • The distance between the study lesion borders is \> 1.0 cm
  • Maximum diameter of each study lesion is 1.8 cm
  • Skin sun sensitivity type I to IV according to Fitzpatrick

Exclusion

  • PDT Non-responder
  • Pre-treatment of the AK lesions eligible for study procedures with pharmaceuticals approved for the treatment of AK during the 4 weeks preceding PDT
  • Pre-treatment of the AK lesions eligible for study procedures during the 2 weeks preceding PDT with keratolytic agents e.g. TCA, urea or salicylic acid containing formulations
  • Pre-treatment with hypericin during the 2 weeks preceding PDT
  • Treatment with systemic retinoids during the 3 months preceding PDT
  • Treatment with cytostatics or radiation during the 3 months preceding PDT
  • Female patients of childbearing potential
  • Patients with clinically relevant suppression of the immune system
  • Diagnosis of Porphyria
  • Skin diseases that might interfere with response evaluation of study PDT
  • Skin sun sensitivity type V or VI according to Fitzpatrick
  • Known intolerance to one or more of the ingredients of the study medication
  • Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written informed consent
  • Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion
  • Suspected lack of compliance

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2007

Estimated Enrollment :

107 Patients enrolled

Trial Details

Trial ID

NCT00308854

Start Date

March 1 2006

End Date

December 1 2007

Last Update

April 11 2008

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Praxis Dr. Popp Dipl.-Med. Weber

Augsburg, Germany, 86179

2

Dermatologisches Zentrum Berlin

Berlin, Germany, 14129

3

Praxisklinik Professor Dr. Uwe Reinhold

Bonn, Germany, 53225

4

Zentrum Dermatologie und Venerologie, Klinikum und Fachbereich Medizin

Frankfurt a.M., Germany, 60590

Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK | DecenTrialz